+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Corporate Reputation of Pharma in 2019 - The Patient Perspective - UK Edition - The Views of 89 UK Patient Groups

  • ID: 5129262
  • Report
  • June 2020
  • Region: United Kingdom
  • 25 Pages
  • PatientView
What 89 UK Patient Groups Think of 16 Pharma Companies in 2019

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • Janssen
  • Merck KGaA
  • MORE

This is the 8th edition of 'The Corporate Reputation of Pharma - from the Perspective of UK Patient Groups'. The 2019 results are drawn from a survey of UK patient groups, conducted November 2019 - February 2020.

About the 2019 Survey of UK Patient Groups

2019’s 89 respondent UK patient groups specialised in 48 different therapy areas.

The 89 UK patient groups had the following geographic remits: 63% had a national geographic remit; 15% an international remit; 7% regional (an area within the UK); and 15% were local.

On UK Patient-Group Relationships with Pharma

  • 56% of the 89 UK patient groups responding to the 2019 survey worked with at least one pharma company.

What this Report Contains

Industry-wide analyses: The report examines the issues of importance to UK patient groups, including: levels of industry innovation; access to treatments; transparency of the industry; and drug pricing. Analyses are reinforced by extensive feedback from 2019's respondent UK patient groups, classified in a 14-page Appendix according to the specialties of the respondent patient groups.

Individual company analyses: The 16 pharma companies are reviewed by 2019's 89 respondent UK patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation.

Key Industry-Wide Findings

Since 2012, when this analysis was first undertaken, UK patient groups have consistently reported lower approval ratings of the pharma industry than patient groups worldwide. However, the percentage of respondent UK patient groups believing the pharma industry’s corporate reputation to be “Excellent” or “Good” increased from 2018 (28%) to 2019 (33%).

On transparency: The ‘Corporate-Reputation’ survey asks respondent patient groups to consider the pharma industry’s record of transparency in three subject areas: pricing issues; sharing of clinical data; and funding of external stakeholders (such as doctors). Only 22% or less of 2019’s respondent UK patient groups stated that the pharmaceutical industry was “Excellent” or “Good” at any of the three types of transparency. Comments made to the survey by respondent UK patient groups reveal that, often, the issue for them was not a failure by industry to be transparent, but more, the industry’s poor levels of communication. As a national patient group specialising in atopic dermatitis/eczema stated: “Make clear any funding or partnership arrangements on the company's website, and for information to be found easily.” Similarly, CCL Support said: “Publish information about funding on their website, and the results of all trials with their drugs.”

On pricing: From the data collected, and feedback received from the respondent UK patient groups, pricing remained an area of dissatisfaction in 2019. As one national patient group specialising in kidney conditions told the survey: “Ensure that the price enables the National Health Service (NHS) to purchase their products - that is, price the products to make them cost-effective.” Just 8% of the 89 respondent UK patient groups judged the industry to be “Excellent” or “Good” at having fair pricing policies in 2019.

On patient engagement in R&D: 2019’s respondent UK patient groups, as in previous years, were clear that not only do they want companies to offer transparent and timely access to clinical-trial data but also that these patient groups wish to be involved throughout the drug research-and-development process. One national patient group specialising in skin disorders noted: “Work more closely with patient groups, so that the pharma company understands the real needs of patients, and contributes directly to improving their lives, alongside the development of new drugs.”

Key Company Findings

Janssen and Gilead continued to dominate the UK league tables for 2019. Two companies, Sanofi and Boehringer Ingelheim, made large jumps up the UK league tables, 2018-2019.

  • Ranked 1st: Janssen was ranked overall 1st out of 16 companies for corporate reputation in 2019 by the 30 respondent UK patient groups familiar with the company. In 2018, Janssen was ranked 2nd out of 19 companies by the UK patient groups familiar with it.
  • Ranked 2nd: Gilead was ranked overall 2nd out of 16 companies for corporate reputation in 2019 by the 24 respondent UK patient groups familiar with the company. In 2018, Gilead was ranked 1st out of 19 companies by the UK patient groups familiar with it.
  • Ranked 3rd: Sanofi was ranked overall 3rd out of 16 companies for corporate reputation in 2019 by the 33 respondent UK patient groups familiar with the company. In 2018, Sanofi was ranked 9th out of 19 companies by the UK patient groups familiar with it.
  • Ranked 4th: Boehringer Ingelheim was ranked overall 4th out of 16 companies for corporate reputation in 2019 by the 27 respondent UK patient groups familiar with the company. In 2018, Boehringer was ranked 17th out of 19 companies by the UK patient groups familiar with it.

One Caveat

A majority of the 89 UK patient groups responding to the 2019 ‘Corporate-Reputation’ survey felt unable to pick out any one company as “Best” at:

  • ensuring patient safety;
  • being transparent;
  • having integrity;
  • providing services ‘beyond the pill’, or at
  • engaging patients in R&D.

However, these UK results are in general conformity with the opinions of 2019’s 1,850 respondent patient groups from all countries.

A note about COVID-19 and this study's results

Covid-19 should have a relatively limited impact on many of the results of the 2019 ‘Corporate-Reputation’ study, because the survey took place (November 2019 to late-February 2020) largely before the crisis became global. However, announcements about Covid-19 by some pharma companies during January and February 2020, may have influenced the views of patient groups responding to the ‘Corporate-Reputation’ survey during its last two months.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • Janssen
  • Merck KGaA
  • MORE

1 Executive summary
7 UK patient-group relationships with pharma, 2019
10 Industry-wide findings, 2019
15 Rankings of 16 pharma companies, 2019 (v. 2018)among UK patient groups familiar with the companies
24 Profiles of the 16 companies, 2019 (v. 2018)
 
APPENDICES
I What UK patient groups say on pharma (and how the industry can improve), 2019/2020
II Profiles of respondent UK patient groups, 2019

TABLES AND CHARTS
2 The key specialty areas of 2019’s respondent UK patient groups
3 Percentage of respondent UK patient groups stating that the industry was “Excellent” or “Good” at adopting fair pricing policies
3 The corporate reputation of the pharmaceutical industry, 2012-2019, Percentage of respondent patient groups UK v. global stating the industry was “Excellent” or “Good”
4 Percentage of respondent UK patient groups stating that the industry was “Excellent” or “Good” at being transparent in pricing policies; sharing of clinical data; and funding of external stakeholders (such as doctors)
4 Percentage of respondent UK patient groups stating that the industry was “Excellent” or “Good” at engaging patients in R&D
5 Percentage of respondent UK patient groups stating “None” or “Do not know” any company that was “Best” at an activity, 2019
6 The rankings of 13 ‘big-pharma’ companies at corporate reputation, 2019 v. 2018 (according to respondent UK patient groups familiar with the companies)
8 UK patient groups: familiarity, and partnerships, with pharma companies, 2019  
9 The types of working relationships that respondent UK patient groups have with pharma companies, 2019
11 The corporate reputation of the pharmaceutical industry, 2019 v. 2018 - compared with that of 8 other healthcare sectors (according to respondent UK patient groups)
11 The corporate reputation of the pharmaceutical industry, 2012-2019 (according to respondent UK patient groups versus patient groups worldwide)
12 The perceived effectiveness of the pharmaceutical industry at carrying out specific activities, 2019 v. 2018(according to respondent UK patient groups)
13 Perceptions of the efficacy of the pharmaceutical industry at various activities of importance to patient groups, 2019 v. previous years (according to respondent UK patient groups)
15 Rankings of 16 individual pharma companies, 2019 v. 2018 (according to respondent UK patient groups familiar with the company)

Profiles of the 16 companies, 2019 v. 2018, Charts and Tables

  • Number of respondent UK patient groups claiming familiarity with the company, 2019.
  • Number of respondent UK patient groups saying that they had a working relationship with the company, 2019.
  • Profile of respondent UK patient groups familiar with the company, 2019: country headquarters; specialties; geographic remit; and types of relationships.
  • Company scores among respondent UK patient groups familiar with the company, and which work with the company, for each of the 12 indicators of corporate reputation, 2019.
  • Percentage of the respondent UK patient groups that work with the company, but which also works with other companies, 2019.  
  • Overall rankings for the company, according to respondent UK patient groups familiar with the company, 2019 v. 2018.
  • Company rankings for each of the 12 indicators, according to respondent UK patient groups familiar with the company, 2019 v. 2018.
  • Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent UK patient groups familiar with the company, 2019.
  • The company’s Patient Corporate Reputation Indexes (PCRIs), 2015-2019 - selected indicators.
Note: Product cover images may vary from those shown

Loading
LOADING...

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly
  • GSK
  • Gilead Sciences/Kite Pharma
  • Janssen
  • Merck & Co/MSD
  • Merck KGaA
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll